ATE339957T1 - Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs - Google Patents

Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Info

Publication number
ATE339957T1
ATE339957T1 AT00973002T AT00973002T ATE339957T1 AT E339957 T1 ATE339957 T1 AT E339957T1 AT 00973002 T AT00973002 T AT 00973002T AT 00973002 T AT00973002 T AT 00973002T AT E339957 T1 ATE339957 T1 AT E339957T1
Authority
AT
Austria
Prior art keywords
breast cancer
tyrosine kinase
egfr tyrosine
kinase inhibitors
treat breast
Prior art date
Application number
AT00973002T
Other languages
English (en)
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of ATE339957T1 publication Critical patent/ATE339957T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00973002T 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs ATE339957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use

Publications (1)

Publication Number Publication Date
ATE339957T1 true ATE339957T1 (de) 2006-10-15

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973002T ATE339957T1 (de) 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Country Status (21)

Country Link
US (1) US7553815B1 (de)
EP (1) EP1272188B1 (de)
JP (1) JP2003513035A (de)
KR (1) KR100785359B1 (de)
CN (1) CN1197577C (de)
AT (1) ATE339957T1 (de)
AU (1) AU779190B2 (de)
BR (1) BR0015194A (de)
CA (1) CA2389411C (de)
CY (1) CY1106285T1 (de)
DE (1) DE60030889T2 (de)
DK (1) DK1272188T3 (de)
ES (1) ES2275556T3 (de)
GB (1) GB9925958D0 (de)
IL (1) IL149176A0 (de)
MX (1) MXPA02004272A (de)
NO (1) NO323206B1 (de)
NZ (1) NZ518696A (de)
PT (1) PT1272188E (de)
WO (1) WO2001032155A2 (de)
ZA (1) ZA200203431B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050038048A1 (en) * 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
AU2002351196A1 (en) * 2001-12-03 2003-06-17 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP1837025A3 (de) * 2002-06-05 2007-12-19 Cedars-Sinai Medical Center Verfahren zur Krebsbehandlung mit Kinaseinhibitoren
WO2005017493A2 (en) * 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
MXPA06003113A (es) 2003-09-19 2006-06-20 Astrazeneca Ab Derivados de quinazolina.
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
EP1982718A4 (de) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd Pharmazeutische zusammensetzung zur krebsbekämpfung
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
EP2899541A1 (de) 2007-03-02 2015-07-29 Genentech, Inc. Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
SG174272A1 (en) * 2009-03-11 2011-10-28 Ardea Biosciences Inc Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
EP0831829B1 (de) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
EP0836605B1 (de) * 1995-07-06 2002-02-06 Novartis AG Pyrolopyrimidine und verfahren zu ihrer herstellung
WO1999060023A1 (en) * 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US20090202167A1 (en) 2006-08-28 2009-08-13 Koninklijke Philips Electronics N.V. Method and apparatus for image enhancement

Also Published As

Publication number Publication date
DE60030889D1 (de) 2006-11-02
KR20020064306A (ko) 2002-08-07
DK1272188T3 (da) 2007-01-29
IL149176A0 (en) 2002-11-10
NO20022065D0 (no) 2002-04-30
KR100785359B1 (ko) 2007-12-18
ES2275556T3 (es) 2007-06-16
NO323206B1 (no) 2007-01-22
EP1272188A2 (de) 2003-01-08
DE60030889T2 (de) 2007-04-05
NZ518696A (en) 2004-12-24
CA2389411A1 (en) 2001-05-10
NO20022065L (no) 2002-06-24
PT1272188E (pt) 2007-01-31
MXPA02004272A (es) 2003-08-20
EP1272188B1 (de) 2006-09-20
WO2001032155A2 (en) 2001-05-10
AU1155901A (en) 2001-05-14
ZA200203431B (en) 2003-02-26
CN1197577C (zh) 2005-04-20
JP2003513035A (ja) 2003-04-08
CN1387437A (zh) 2002-12-25
CA2389411C (en) 2009-09-01
WO2001032155A3 (en) 2002-05-10
GB9925958D0 (en) 1999-12-29
US7553815B1 (en) 2009-06-30
AU779190B2 (en) 2005-01-13
CY1106285T1 (el) 2011-10-12
BR0015194A (pt) 2002-06-18

Similar Documents

Publication Publication Date Title
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
BR9910511A (pt) Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
MY169308A (en) Treatment of tnf? related disorders
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE404202T1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE381930T1 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272188

Country of ref document: EP

REN Ceased due to non-payment of the annual fee